Trouble Viewing This Email: Click Here

December 07, 2021

FOUNDING MEMBER OF

Novavax tailoring Covid-19 vaccine to Omicron variant while advancing campus expansion plans - Washington Business Journal

The company said Thursday it’s implementing “a two-pronged variant strategy” for the variant.

United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022 | BioSpace

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2022. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list was announced on December 2, 2021, available on Newsweek’s website, recognizes the top 500 most responsible companies in the United States, spanning 14 industries.

Life Sciences Business Strategist - Open Position!

BioHealth Innovation (BHI) is an innovation intermediary that facilitates the commercialization of emerging technologies in the BioHealth Capital Region (Maryland, DC and Virginia).

BHI is seeking a Life Sciences Business Strategist to join its team in Rockville, Maryland. This position provides the opportunity to leverage scientific knowledge to evaluate the commercial potential of emerging technologies and provide recommendations on go-to-market strategies.

This is a customer facing role with a focus on supporting clients in the development of commercial analyses and federal grant proposals.

Click here for more details.

PharmaShots Interview: Cartesian Therapeutics’s Dr. Murat Kalayoglu Shares Insight on RNA Cell Therapy for an Autoimmune Disease

In an interview with PharmaShots, Dr. Murat Kalayoglu, MD, Ph.D., President, and Chief Executive Officer at Cartesian Therapeutics shared his insights on the P-I/IIa study of Descartes-08 for the treatment of the chronic autoimmune disorder generalized myasthenia gravis (gMG)

Shots:

Descartes-08 is an autologous T-cell product that is engineered with RNA to encode for CAR
The company focuses to use RNA instead of DNA to engineer the cell target that helps to target antigen without increasing the risk of these cells proliferating out of control and causing the typical CAR-T cell toxicities
Cartesian has currently three RNA cell therapies i.e., Descartes-08 & Descartes-11 which are being developed for multiple myeloma, high-risk patients, newly diagnosed multiple myeloma while Descartes-30 is an off-the-shelf, RNA engineered cell therapy. The company is expected to complete the P-II studies in 2022 and registration studies in 2024

Baltimore Startup Rasio Therapeutics Raises $1.5M for Software to Develop Drugs

A Baltimore startup that uses computer software to develop cancer drugs has raised $1.5 million in new funding, according to a recent filing.

Rasio Therapeutics is part of Early Charm Ventures, a Baltimore company focused on running and growing startups. The $1.5 million investment comes from BlueDot Bio, a relatively new investment company, said Ken Malone, managing director of Early Charm Ventures.

Click here to read more via Bizjournals (subscription required)

Possible Life Sciences and Biotechnology Office Building Coming to Pike & Rose in Location Currently Occupied by Bark Social - The MoCo Show

Possible Life Sciences and Biotechnology Office Building Coming to Pike & Rose in Location Currently Occupied by Bark Social

We recently learned of plans for a potential new office building that could be constructed at 935 Prose Street in Pike & Rose, the current site of Bark Social.

The plans, authored by Scheer Partners, state that the new building will be a 10-story trophy-class, state-of-the-art research/lab building that marries iconic design, and superior lab functionality. The architectural plans show lab space, office space, a fitness center, outdoor green terrace, conference facility, and more.

Image: https://mocoshow.com

Francis Collins

About a decade before becoming NIH Director—a position from which he will step down at year’s end—Francis S. Collins, M.D., Ph.D., was at the center of one of the hottest debates in the nascent days of genomics: How many protein-coding sequences comprise the human genome?

Image: Francis Collins

CoSolve challenges

CoSolve is a biannual, global Open Innovation programme seeking collaborators with innovative solutions to real research challenges. These challenges lie within our R&D research focus areas and require solutions that are immediately translatable. We are looking for collaborators from start-ups and early stage biotechs with expertise in these specialised areas, who can bring innovative ideas that can be rapidly translated into tangible solutions. Working together, your ideas could help shape the development and delivery of new therapies and bring them to patients sooner.

Biohealth Startup to Establish $5M HQ in Loudoun - Loudoun Now

Athari Biosciences has selected Loudoun County for its new corporate headquarters.

The project includes a wet lab, a tech lab, research and development and office space and is expected to open in early 2022. The project is expected to create 50 jobs with a total investment of $5 million, according to the county’s Department of Economic Development.

The Board of Supervisors will consider a cash incentive of $120,000 to support the completion of the lab space at its Dec. 7 meeting. The incentive has been proposed by the economic development department, which worked with Athari’s leadership team in the search for the firm’s long-term home in the region.